Market revenue in 2023 | USD 355.8 million |
Market revenue in 2030 | USD 536.4 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Large molecules |
Fastest growing segment | Small molecules |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Large Molecules, Small molecules |
Key market players worldwide | Boehringer Ingelheim, Catalent Inc, Baxter International Inc, Eurofins Scientific SE, Recipharm, Fresenius SE & Co KGaA, Novartis AG ADR, Recro Pharma, Symbiosis Pharmaceutical Services, MabPlex International |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fill-finish pharmaceutical contract manufacturing market will help companies and investors design strategic landscapes.
Large molecules was the largest segment with a revenue share of 67.09% in 2023. Horizon Databook has segmented the Australia fill-finish pharmaceutical contract manufacturing market based on large molecules, small molecules covering the revenue growth of each sub-segment from 2018 to 2030.
Australia has a highly advanced healthcare industry. The increasing awareness of the need for the early detection of lifestyle and chronic diseases is boosting the pharmaceutical industry in the country. The Australian government has undertaken various schemes to provide medicines at subsidized rates.
For instance, as per the Pharmaceutical Benefits Scheme (PBS), medicines are available for all eligible patients at a subsidized cost. The abovementioned factors are expected to improve & promote the demand for fill-finish pharmaceutical manufacturing in the country, thus, boosting the demand for contract manufacturing services. Some of the key players contributing to the country’s market growth are Patheon, Althea Group, Catalent, Inc., and Novartis.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia fill-finish pharmaceutical contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia fill-finish pharmaceutical contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account